Tabriz University of Medical Sciences Advanced Pharmaceutical Bulletin 2228-5881 15 4 2025 11 15 The Art of Nanoimmunobiotechnomedicine in Depression Management 750 765 10.34172/apb.025.42757 EN Dito Anurogo https://orcid.org/0000-0002-3292-3139 Ririn Tri Ratnasari https://orcid.org/0000-0003-1126-4012 Novi Irmania https://orcid.org/0000-0001-6469-9330 Muhammad Sobri Maulana Kholis Abdurachim Audah Novi Sekar Sari Maratu Soleha Amir Su’udi Ahmad Hafidul Ahkam Andi Weri Sompa Riswal Nafi’ Siregar Maulida Mazaya Riri Rimbun Anggih Chaidir Azzah Khoridah Maulidiya Suryani As’ad Ami Febriza Achmad Nur Rahmah Awaliah Gangga Anuraga Waode Fifin Ervina Noorman Rinanto Era Catur Prasetya Tzu-Jen Kao Tria Astika Endah Permatasari Arli Aditya Parikesit Nguyen Quoc Khanh Le Nadhirah Nordin REVIEW 10.34172/apb.025.42757 2024 12 30 2025 09 24 Purpose: To explore the role of nanoimmunobiotechnomedicine in depression management, emphasizing how nanotechnology and immunobiology offer innovative approaches to understanding and treating depression. We investigated the molecular mechanisms underlying depression and integrated multi-omics approaches such as genomics, epigenomics, and bioinformatics to advance therapeutic strategies. Methods: An interdisciplinary approach was applied, synthesizing data from epigenetics, nutrigenomics, and advanced bioinformatics. Furthermore, molecular and cellular neuroscience techniques were utilized alongside pharmacogenomics to deepen the understanding of depression. Results: Findings highlight the effectiveness of nano-based interventions, like targeted drug delivery systems and anti-inflammatory treatments, in reducing neuroinflammation and enhancing neuroplasticity. Multi-omics data show the importance of neurotrophic factors and gut-brain axis interactions in depression management. Additionally, pharmacogenetics suggests personalized treatment strategies, tailoring therapeutic responses based on individual genetic profiles. Conclusion: Nanoimmunobiotechnomedicine represents a frontier for personalized depression therapies. The integration of nanotechnology and immunobiology enhances bioavailability and specificity in targeting depressive disorders at the molecular level. This convergence of molecular biology, and bioinformatics studies holds significant potential to revolutionize depression treatment, offering more effective and individualized solutions for better mental health outcomes.